Enfortumab vedotin (1) – Padcev®

Muscle-invasive bladder cancer, neoadjuvant/adjuvant therapy following cystectomy, in combination with pembrolizumab

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Enfortumab vedotin
Brand name Padcev®
Pharm. company Astellas Pharma GmbH
G-BA Procedure ID D-1396
Therapeutic area Oncological diseases
Reason for procedure New therapeutic indication

Associated procedures



<< List of all resolutions